Adlai Nortye Ltd. (ANL)

NASDAQ: ANL · Real-Time Price · USD

12.17

-1.08 (-8.15%)

Apr 28, 2026, 4:00 PM EDT - Market closed

Adlai Nortye Employees

Adlai Nortye had 109 employees as of December 31, 2025. The number of employees decreased by 14 or -11.38% compared to the previous year.

Employees

109

Change (1Y)

-14

Growth (1Y)

-11.38%

Revenue / Employee

$45,872

Profits / Employee

-$325,945

Market Cap

486.80M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2025	109	-14	-11.38%
Dec 31, 2024	123	-4	-3.15%
Dec 31, 2023	127	-2	-1.55%
Dec 31, 2022	129	-	-

Related Stocks

Company Name	Employees
MiMedx Group	808
Valneva SE	674
Lyell Immunopharma	300
4D Molecular Therapeutics	196
ADC Therapeutics	193
Verastem	102
Fulcrum Therapeutics	55
Contineum Therapeutics	51

Employee Rankings

ANL News

12 days ago - Adlai Nortye Announces $150.0 Million Private Placement Equity Financing - GlobeNewsWire
2 months ago - Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewsWire
3 months ago - Adlai Nortye Announces $140.0 Million Private Placement Equity Financing - GlobeNewsWire
4 months ago - Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - GlobeNewsWire
7 months ago - Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
2 years ago - Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewsWire
2 years ago - Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - GlobeNewsWire
2 years ago - Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - GlobeNewsWire